Corbus Pharmaceuticals Holdings, Inc. (CRBP) - 10-Q Summary
Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage oncology and obesity company. This report covers the quarterly period ended June 30, 2025. The company has no product revenue and is focused on developing three primary candidates: CRB-701 (oncology ADC), CRB-601 (oncology antibody), and CRB-913 (obesity treatment).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(17.7) million | $(34.6) million | $(16.9) million |
| Operating Expenses | $19.2 million | $38.9 million | $20.6 million |
| R&D Expenses | $15.2 million | $30.8 million | $12.6 million |
| Cash & Investments | $116.6 million (as of June 30, 2025) | ||
| Accumulated Deficit | $511.5 million (as of June 30, 2025) | ||
| Debt | $0 (K2 Loan repaid in August 2024) |
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses surged 121% in Q2 2025 and 144% YTD 2025 compared to the prior year. This reflects accelerated clinical activity across all three programs:
- CRB-701: Enrollment in the Western Phase 1/2 study and initiation of a PD-1 combination arm.
- CRB-601: Ongoing Phase 1 dose escalation and combination studies.
- CRB-913: Initiation of Multiple Ascending Dose (MAD) trials and manufacturing for Phase 1b.
- Debt Elimination: The company had no interest expense in 2025, as the K2 HealthVentures loan was fully repaid in August 2024. This contrasts with $1.5 million in interest expense for the six months ended June 30, 2024.
- Investment Portfolio: Investments decreased from $131.9 million (Dec 31, 2024) to $96.5 million (June 30, 2025) due to maturities and sales used to fund operations, though net cash from investing activities was positive ($35.9 million) due to proceeds exceeding purchases.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects cash, cash equivalents, and investments of approximately $116.6 million to be sufficient to meet operating requirements through the second quarter of 2027.
- Clinical Milestones:
- CRB-701: Dose expansion data expected at ESMO in October 2025; Recommended Phase 2 dose (RP2D) expected in Q4 2025.
- CRB-601: Dose escalation data expected in Q4 2025.
- CRB-913: Phase 1 MAD trial completion expected in Q3 2025; Phase 1b initiation expected in Q4 2025.
- Risks:
- Capital Needs: The company will require significant additional capital to continue clinical trials. Failure to raise funds could force delays or elimination of trials.
- Trade Policy: New U.S. tariffs announced in 2025 may increase global clinical trial costs and impact supply chains.
- Profitability: The company has never been profitable and expects to incur operating losses for the foreseeable future.
Investor Verification Checklist
- Verify the timeline for the CRB-701 dose expansion data presentation at ESMO (October 2025) and the identification of the RP2D.
- Monitor the CRB-913 Phase 1 safety profile, specifically regarding neuropsychiatric events, as the company aims to differentiate from prior CB1 inverse agonists.
- Assess the impact of 2025 U.S. tariffs on the cost of imported clinical drug supplies and materials.
- Review the Open Market Sale Agreement status; approximately $76.4 million remains available for issuance as of June 30, 2025.
- Confirm the cash runway projection of Q2 2027 against the accelerating burn rate driven by expanded clinical enrollment.